Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers
    2.
    发明公开
    Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers 有权
    Chinolin-4-ylderivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker

    公开(公告)号:EP1090917A1

    公开(公告)日:2001-04-11

    申请号:EP00121561.5

    申请日:2000-10-02

    CPC分类号: C07D401/04 C07D401/14

    摘要: The present invention relates to compounds of the general formula
    wherein

    R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen;
    R 2 is hydrogen, lower alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl-methanol or -NHCH 2 CHROH;
    R 3 is hydrogen or halogen;
    R is hydrogen, lower alkyl or -CH 2 OH;
    n is 1 or 2;
       and to pharmaceutically acceptable acid addition salts thereof.
    Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity in mediating processes underlying development of CNS as well as learning and memory formation.

    摘要翻译: 本发明涉及通式为CHEM的化合物,其中R 1为氢,低级烷基,低级烷氧基,羟基,氨基,硝基,氰基,低级烷基 - 氨基,二低级烷基 - 氨基或卤素; R 2是氢,低级烷基,氨基,吡咯烷-3-醇,吡咯烷-2-基 - 甲醇或-NHCH 2 CHROH; R 3是氢或卤素; R为氢,低级烷基或-CH 2 OH; n为1或2; 和其药学上可接受的酸加成盐。 本发明化合物是NMDA(N-甲基-D-天冬氨酸) - 受体亚型选择性阻断剂,其在调节CNS发育过程中的神经元活性和可塑性方面具有关键作用,以及学习和记忆形成。

    4-hydroxy-piperidine derivatives
    3.
    发明公开
    4-hydroxy-piperidine derivatives 失效
    4-羟基 - 哌啶衍生物

    公开(公告)号:EP0824098A1

    公开(公告)日:1998-02-18

    申请号:EP97111742.9

    申请日:1997-07-10

    摘要: The present invention relates to compounds of the general formula
    wherein

    X is -O-, -NH-, -CH 2 -, -CH=, -CO 2 -, -CONH-, -CON(lower alkyl)-, -S- and -SO 2 -;
    R 1 - R 4 are, independently from each other hydrogen, halogen, hydroxy, amino, nitro, lower-alkyl-sulfonylamido, 1- or 2-imidazolyl, 1-(1,2,4-triazolyl) or acetamido;
    R 5 , R 6 are, independently from each other hydrogen, lower-alkyl, hydroxy, lower alkoxy or oxo;
    R 7 -R 10 are, independently from each other hydrogen, lower-alkyl, halogen, trifluoromethyl or lower-alkoxy;
    n is 0 or 1;
    and to pharmaceutically acceptable acid addition salts thereof.
    Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers.

    摘要翻译: 本发明涉及通式如下的化合物,其中X是-O - , - NH - , - CH 2 - , - CH =, - CO 2 - , - CONH-, - CON(低级烷基) SO2-; R 1 -R 4彼此独立地为氢,卤素,羟基,氨基,硝基,低级烷基 - 磺酰氨基,1-或2-咪唑基,1-(1,2,4-三唑基)或乙酰氨基; R5,R6彼此独立地是氢,低级烷基,羟基,低级烷氧基或氧代; R7-R10相互独立地为氢,低级烷基,卤素,三氟甲基或低级烷氧基; n是0或1; 和其药学上可接受的酸加成盐。 本发明的化合物是NMDA(N-甲基-D-天冬氨酸) - 受体亚型选择性阻断剂。

    Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
    9.
    发明公开
    Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers 有权
    Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern

    公开(公告)号:EP0982026A2

    公开(公告)日:2000-03-01

    申请号:EP99115114.3

    申请日:1999-08-09

    摘要: The present invention relates to the use of compounds of the general formula
    wherein

    Ar 1 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by hydroxy, lower alkoxy, nitro, amino or methanesulfonamide;
    Ar 2 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by lower alkyl or halogen;
    X is C, CH, C(OH) or N;
    Y is -CH 2 -, CH or O
    Z -CH 2 -, -CH(CH 3 )- or -C(CH 3 ) 2 -;
    R 1 is hydrogen, lower alkyl or acetyl;
    A is C=O or -(CHR 2 ) n -, wherein R 2 is hydrogen, lower alkyl or hydroxy-lower alkyl;
    B is -(CH 2 ) n -, O, -CH(OH)(CH 2 ) n -, -CH(CH 2 OH)(CH 2 ) n -, -(CH 2 ) n CH(OH)- or -CH(CH 2 OH)-;
    --- may be a bond and
    n is 0-4
    and to pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments which represent therapeutic indications for NMDA receptor subtype specific blockers.

    摘要翻译: 本发明涉及通式的化合物的用途,其中Ar 1是任选被羟基,低级烷氧基,硝基,氨基或甲磺酰胺取代的苯基,萘基或四氢萘基; Ar 2是任选被低级烷基或卤素取代的苯基,萘基或四氢萘基; X是C,CH,C(OH)或N; Y是-CH 2 - ,CH或O Z -CH 2 - , - CH(CH 3) - 或-C(CH 3)2 - ; R 1是氢,低级烷基或乙酰基; A是C = O或 - (CHR 2)n - ,其中R 2是氢,低级烷基或羟基 - 低级烷基; B是 - (CH 2)n - ,O,-CH(OH)(CH 2)n - , - CH(CH 2 OH)(CH 2)n - , - (CH 2)n CH(OH) - 或-CH ; ---可以是键,n是0-4,以及其药学上可接受的酸加成盐,用于制备代表NMDA受体亚型特异性阻断剂治疗适应症的药物。

    MPTP affinity labels
    10.
    发明公开
    MPTP affinity labels 有权
    MPTPAffinitätsmarker

    公开(公告)号:EP1468995A1

    公开(公告)日:2004-10-20

    申请号:EP04008411.3

    申请日:2004-04-07

    摘要: The present invention provides the use of compounds of general formula I and compounds of general formula II as modulators and affinity labels of the MPTP complex. Furthermore, the present invention provides methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent that modulates the activity of the MPTP complex, specifically methods for identifying an active agent that modulates the activity of the MPTP complex by interacting with the VDAC1 component. Moreover, novel compounds of general formula I are provided by the present invention.

    摘要翻译: 本发明提供通式I化合物和通式II化合物作为MPTP复合物的调节剂和亲和标记物的用途。 此外,本发明提供了调节MPTP复合物的活性的方法,用于确定MPTP复合物的组分的存在的方法,以及用于鉴定调节MPTP复合物的活性的活性剂的方法,具体地说, 活性剂通过与VDAC1组分相互作用来调节MPTP复合物的活性。 此外,通式I的新化合物由本发明提供。